Akademik Veri Yönetim Sistemi
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.33, sa.4, ss.227-239, 2023 (SCI-Expanded)
Vitamin D consists of fat-soluble pro -hormones and plays role in Ca2 and P transport and bone mineralization. While it has been observed that various cancer formations decrease with higher levels of vitamin D, it has been found that individuals with hematological diseases have lower levels. Herein, we aimed to investigate the relationship between vitamin D levels and treatment response rates, survival and clinical characteristics in hematological malignancies with our study. A total of 250 patients who applied to the Hematology Clinic of Ankara Diskapi Yildirim Beyazit Education and Research Hospital between 2013 and 2022 were included in the study. Patients' data were retrospectively analyzed. 10 of the patients had acute lymphoblastic leukemia (ALL), 39 had Acute Myeloid Leukemia (AML), 49 had Diffuse Large B -Cell Lymphoma (DLBCL), 32 had Hodgkin Lymphoma (HL), 51 had Chronic Lymphocytic Leukemia (CLL), 63 had Multiple Myeloma (MM) and 6 had Mantle Cell Lymphoma (MCL). AML patients with low vitamin D levels were found to have higher hemoglobin levels (p= 0.012). DLBCL patients with low vitamin D levels, had higher beta 2 microglobulin levels (p= 0.036). In CLL patients, those with low vitamin D levels were found to have higher absolute lymphocyte count (p= 0.008) and lymphocyte ratios (p= 0.003). MM patients with low vitamin D levels were found to have more CRAB symptoms (p= 0.045). In regression analysis borderline significant correlation has been found between vitamin D levels and the rate of mortality in MM patients. Our study revealed that vitamin D levels may play an important role in the prognosis of hematological malignancies.